Search Results - "Margeli Vila, Mireia"

Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients by Pascual, Javier, Gil-Gil, Miguel, Proszek, Paula, Zielinski, Christoph, Reay, Alistair, Ruiz-Borrego, Manuel, Cutts, Rosalind, Ciruelos Gil, Eva M, Feber, Andrew, Muñoz-Mateu, Montserrat, Swift, Claire, Bermejo, Begoña, Herranz, Jesus, Margeli Vila, Mireia, Antón, Antonio, Kahan, Zsuzsanna, Csöszi, Tibor, Liu, Yuan, Fernandez Garcia, Daniel, Garcia-Murillas, Isaac, Hubank, Michael, Turner, Nicholas C, Martín, Miguel

“…Prognostic and predictive biomarkers to CDK4/6 inhibitors are lacking. Circulating tumour DNA (ctDNA) can be used to profile these patients and dynamic changes…”
Get full text

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer by Guerrero-Zotano, Ángel, Belli, Stefania, Zielinski, Christoph, Gil-Gil, Miguel, Fernandez-Serra, Antonio, Ruiz-Borrego, Manuel, Ciruelos Gil, Eva Maria, Pascual, Javier, Muñoz-Mateu, Montserrat, Bermejo, Begoña, Margeli Vila, Mireia, Antón, Antonio, Murillo, Laura, Nissenbaum, Bella, Liu, Yuan, Herranz, Jesús, Fernández-García, Daniel, Caballero, Rosalía, López-Guerrero, José Antonio, Bianco, Roberto, Formisano, Luigi, Turner, Nicholas, Martín, Miguel

“…In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase…”
Get full text

Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer by Mariscal Martínez, Antonio, Vives Roselló, Irene, Salazar Gómez, Angela, Catanese, Alessandro, Pérez Molina, Mariola, Solà Suarez, Montserrat, Pascual Miguel, Iciar, Blay Aulina, Lidia, Ríos Gozálvez, Cristian, Julián Ibáñez, José Francisco, Rodríguez Martínez, Paula, Martínez Román, Sergio, Margelí Vila, Mireia, Luna Tomás, Miguel Angel

“…To assess the safety and effectiveness of magnetic seeds in preoperative localization and surgical dissection of metastatic axillary lymph nodes (LN+) in…”
Get full text

Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck by Cirauqui, Beatriz Cirauqui, Peguera, Adrià Bernat, Pi-Sunyer, Ariadna Quer, Ferrando-Díez, Angelica, Serrano, Jose Luis Ramírez, Viñolas, Marta Domenech, García, Iris Teruel, García, Vanesa Quiroga, Oukadour, Imane Chaib, Valencia, Andrea González, Vergara, Pilar Hernández, de Aguirre Egaña, Itziar, Herrero, Cristina Queralt, Carbonell, Oscar Mesía, Paradís, Assumpció López, Esteve, Anna, Vila, Mireia Margelí, Rosell, Rafael, Martínez-Cardús, Anna, Mesía, Ricard

“…Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive disease with poor prognosis. It is known that the activation of STAT3 signaling pathways…”
Get full text

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study by Martín, Miguel, Ruiz Simón, Amparo, Ruiz Borrego, Manuel, Ribelles, Nuria, Rodríguez-Lescure, Álvaro, Muñoz-Mateu, Montserrat, González, Sonia, Margelí Vila, Mireia, Barnadas, Agustí, Ramos, Manuel, Del Barco Berron, Sonia, Jara, Carlos, Calvo, Lourdes, Martínez-Jáñez, Noelia, Mendiola Fernández, César, Rodríguez, César A, Martínez de Dueñas, Eduardo, Andrés, Raquel, Plazaola, Arrate, de la Haba-Rodríguez, Juan, López-Vega, Jose Manuel, Adrover, Encarna, Ballesteros, Ana Isabel, Santaballa, Ana, Sánchez-Rovira, Pedro, Baena-Cañada, José M, Casas, Maribel, del Carmen Cámara, María, Carrasco, Eva Maria, Lluch, Ana

“…Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a…”
Get full text

effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial by de Azambuja, Evandro, McCaskill-Stevens, Worta, Francis, Prudence, Quinaux, Emmanuel, Crown, John P. A, Vicente, Malou, Giuliani, Rosa, Nordenskjöld, Bo, Gutiérez, Jorge, Andersson, Michael, Vila, Mireia Margeli, Jakesz, Raimund, Demol, Jan, Dewar, Joanna, Santoro, Armando, Lluch, Ana, Olsen, Steven, Gelber, Richard D, Di Leo, Angelo, Piccart-Gebhart, Martine

“…Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic…”
Get full text

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer by Pascual, Tomás, Oliveira, Mafalda, Ciruelos, Eva, Bellet Ezquerra, Meritxell, Saura, Cristina, Gavilá, Joaquin, Pernas, Sonia, Muñoz, Montserrat, Vidal, Maria J, Margelí Vila, Mireia, Cejalvo, Juan M, González-Farré, Blanca, Espinosa-Bravo, Martin, Cruz, Josefina, Salvador-Bofill, Francisco Javier, Guerra, Juan Antonio, Luna Barrera, Ana María, Arumi de Dios, Miriam, Esker, Stephen, Fan, Pang-Dian, Martínez-Sáez, Olga, Villacampa, Guillermo, Paré, Laia, Ferrero-Cafiero, Juan M, Villagrasa, Patricia, Prat, Aleix

“…Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently,…”
Get full text

Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer by Vila, Mireia Margelí, Barco Berron, Sonia del, Gil-Gil, Miguel, Ochoa-Arnedo, Cristian, Vázquez, Rafael Villanueva

“…Metastatic breast cancer (MBC) diagnosis in young women negatively impacts on quality of life (QoL) and daily activities, disrupting their life project and…”
Get full text

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study by MARTIN, Miguel, RUIZ, Amparo, MUNOZ-MATEU, Montserrat, DORCA RIBUGENT, Joan, LOPEZ-VEGA, José Manuel, JARA, Carlos, ESPINOSA, Enrique, MENDIOLA FERNANDEZ, César, ANDRES, Raquel, RIBELLES, Nuria, PLAZAOLA, Arrate, SANCHEZ-ROVIRA, Pedro, RUIZ BORREGO, Manuel, SALVADOR BOFILL, Javier, CRESPO, Carmen, CARABANTES, Francisco J, SERVITJA, Sonia, IGNACIO CHACON, José, RODRIGUEZ, César A, HERNANDO, Blanca, ALVAREZ, Isabel, CARRASCO, Eva, LLUCH, Ana, BARNADAS, Agustí, GONZALEZ, Sonia, CALVO, Lourdes, MARGELI VILA, Mireia, ANTON, Antonio, RODRIGUEZ-LESCURE, Alvaro, SEGUI-PALMER, Miguel Angel

“…Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most…”
Get full text

Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report by Quiroga García, Vanesa, Cirauqui Cirauqui, Beatriz, Tobey Robaina, Lyan, López Sisamon, David, Hardy-Werbin, Max, Blanca, Ana Belén, Margelí Vila, Mireia

“…Cancer patients with severe renal dysfunction represent a challenge for the physician. This is the first case report on the use of denosumab in a dialysis…”
Get full text

CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study by Pascual, Javier, Gil-Gil, Miguel, Zielinski, Christoph, Hills, Margaret, Ruiz-Borrego, Manuel, Ciruelos, Eva M., Garcia-Murillas, Isaac, Muñoz, Montserrat, Bermejo, Begoña, Swift, Claire, Vila, Mireia Margeli, Antón Torres, Antonio, Nissenbaum, Bella, Murillo, Laura, Liu, Yuan, Herranz, Jesus, Caballero, Rosalia, Guerrero-Zotano, Angel, Turner, Nicholas C., Martin, Miguel

“…Abstract only 1014 Background: The randomized PEARL trial found no superiority of palbociclib plus endocrine therapy over capecitabine in patients (pts) with…”
Get full text

Clinical algorithm to predict who may benefit from CDK4/6 inhibitors in patients (p) with estrogen receptor positive and HER-2 negative (ER+/Her2-) metastatic breast cancer (MBC) by Felip-Falgàs, Eudald, Teruel, Iris, García Mosquera, Juan José, Erasun, Carlos, Quiroga Garcia, Vanesa, Angelats, Laura, España, Sofia, Cucurull, Marc, Cirauqui, Beatriz, Vila, Mireia Margeli

“…Abstract only…”
Get full text

Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study by Martin, Miguel, Zielinski, Christoph, Ruiz-Borrego, Manuel, Carrasco, Eva Maria, Ciruelos, Eva, Muñoz, Montserrat, Bermejo, Begoña, Vila, Mireia Margeli, Turner, Nicholas C., Casas, Maribel, Anton, Antonio, Murillo Jaso, Laura, Lang, Istvan, Bartlett, Cynthia Huang, Koehler, Maria, Martin, Nuria, Corsaro, Massimo, Swift, Claire, Nisenbaum, Bella, Gil Gil, Miguel J.

“…Abstract only 1022 Background: Prior retrospective data has shown ESR1 mutation is an acquired resistant mechanism to AI. However, little is known about ist…”
Get full text

First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 (RegistEM) by Jara, Carlos, Alvarez, Isabel, Vila, Mireia Margeli, Rodriguez, Cesar Augusto, Martinez, Purificacion, Batista, J. Norberto, Alonso Romero, Jose Luis, Antolín Novoa, Silvia, Ruíz, Sofía, Guerrero, Angel, Tusquets, Ignasi, Anton, Antonio, Chacon, Jose Ignacio, Rodríguez-Lescure, Álvaro, Tibau Martorell, Ariadna, Varela Ferreiro, Silvia, Miralles, Juan José, Bezares, Susana, Rojo, Federico, López-Tarruella, Sara

“…Abstract only 1077 Background: In Spain there is limited prospective data for unresectable locally advanced breast cancer (ULABC) or metastatic breast cancer…”
Get full text

Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients by Quiroga-García, Vanesa, Cirauqui-Cirauqui, Beatriz, Bugés-Sánchez, Cristina, Luna-Tomás, Miguel Ángel, Castellà-Fernández, Eva María, Mariscal-Martínez, Antonio, Margelí-Vila, Mireia

“…Background: Treatment with aromatase inhibitors (AIs) followed by surgery is often recommended for women with locoregional hormone-sensitive breast cancer…”
Get full text

Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial by Martin, Miguel, Lluch, Ana, Ruiz, Amparo, Ruiz Borrego, Manuel, Barnadas, Agust, Gonzalez, Sonia, Calvo, Lourdes, Margeli Vila, Mireia, Anton, Antonio, Rodriguez-Lescure, Alvaro, Seguí-Palmer, Miguel Angel, Munoz-Mateu, Montserrat, Dorca Ribugent, Joan, Lopez-Vega, Jose Manuel, Mendiola Fernandez, Cesar, Andres, Raquel, Plazaola, Arrate, Rodriguez, Cesar, Casas, Maria Isabel, Carrasco, Eva Maria

“…Abstract only 1001 Background: Adjuvant weekly paclitaxel (wP) sequential to anthracyclines improves the outcome of operable node-positive BC patients (pts)…”
Get full text

Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastatic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study by Zamora, Pilar, Fresno-Vara, Juan Angel, Gámez-Pozo, Angelo, Perez-Carrion, Ramon, Manso, Luis, Crespo Massieu, Carmen, Mendiola, Cesar, Alvarez, Isabel, Margeli Vila, Mireia, Bayo Calero, Juan Lucas, Gonzalez, Xavier, Santaballa, Ana, Ciruelos Gil, Eva Maria, Afonso Gomez, Ruth, Lao Romera, Juan, Catalan, Gustavo, Alvarez Gallego, Jose Valero, Miramon Lopez, Jose, Salvador Bofill, Francisco Javier, Ruiz Borrego, Manuel

“…Abstract only e11081 Background: Trastuzumab has shown an improvement in survival outcomes among patients with HER2+ metastatic breast cancer (MBC)…”
Get full text

Abstract P1-15-04: Features of HER2+ metastasic patients (pts) from a prospective registry of advanced breast cancer (ABC), GEICAM/2014-03 (RegistEM) by Álvarez, Isabel, Guerrero-Zotano, Ángel, Cruz, Josefina, Martínez, Purificación, Hernández, María, Rodríguez, César A, Rodríguez-Lescure, Álvaro, Antolín, Silvia, Adrover, Encarna, Andrés, Raquel, Falo, Catalina, Chacón, Jose Ignacio, Miguel, Ana, Servitja, Sonia, Gramaje, Maria Galán, Vila, Mireia Margelí, Raposo, César Gómez, Echarri, María Jose, Villanueva, Rafael, Martorell, Ariadna TIbau, Ferreiro, Silvia Varela, Campo, Ruth, Miralles, Juan Jose, Bezares, Susana, Rojo, Federico, López-Tarruella, Sara

“…Background: The RegistEM study is a non-interventional study that is providing prospective data from around 1900 ABC pts (females and males) diagnosed with…”
Get full text

Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3) by Prat, Aleix, Cejalvo, Juan M., Pare, Laia, Martínez-Sáez, Olga, Vila, Mireia Margelí, Falato, Claudette, Cruz, Josefina, de Dios, Miriam Arumí, Vidal, Maria J, Guerra, Juan Antonio, Barrera, Ana Maria Luna, Tolosa, Pablo, Salvador-Bofill, Francisco Javier, Pernas, Sonia, Gonzáles-Farré, Blanca, Sanfeliu, Esther, Ciruelos, Eva, Serra, Violeta, Espinosa-Bravo, Martin, Izarzugaza, Yann, Esker, Stephen, Fan, Pang-Dian, Villacampa, Guillermo, Ferrero-Cafiero, Juan M, Pascual, Tomás, Oliveira, Mafalda

“…Introduction Patritumab deruxtecan (U3-1402; HER3-DXd) is a HER3-directed antibody drug conjugate with demonstrated clinically meaningful antitumor activity…”
Get full text

Abstract CT154: Multicenter open-label, phase II trial, to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI) for progressing brain metastases in patients with HER2-negative breast cancer (The Phenomenal Study) by Cortés, Javier, Paez, David, García, José Manuel Pérez, Tormo, Salvador Blanch, Parraga, Kepa Amillano, Borrego, Manuel Ruiz, Torres, Antonio Antón, Fernández, María, Conejo, Emilio Alba, Palmer, Miguel Ángel Seguí, Ribugent, Joan Dorca, López López, Rafael, Vila, Mireia Margelí, Aguirre, Elena, Llombart, Antonio

“…Background: HER2-negative metastatic breast cancer (MBC) patients with central nervous system (CNS) involvement previously treated with a local therapy had…”
Get full text